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Background 
HCV induces chronic liver disease, which is characterized by a persistent hepatic 
parenchyma inflammatory process that may progress to cirrhosis and hepatocarcinoma. 
Genetic differences among the infected hosts can determine the progression of the 
infection, causing different individuals to respond in different ways to the viral infection. 
Cytokines have become the focus of many scientific studies, as there is evidence of the 
contribution of genetic factors to the imbalance of the inflammatory profile of the patient, 
which directly affects the clinical outcome and the severity of hepatitis C and other 
infectious diseases. 
Material/Methods 
Our study included data of 244 patients (Average age 39.1 years, 55.7% men, 44.3% 
female) with chronic hepatitis C (HCV genotype 1 to 4). In addition to many demographic 
characteristics also laboratory parameters (ALT, AST, g-GT,bilirubin, Quick) and hepatitis-
related parameters (hepatitis C viral load, validation of hepatitis A or/and B and 
duration/type of the anti- HCV therapy) were obtained. 
From 186 patients grade of liver fibrosis was determined after METAVIR. Fibrosis 
abundance and rate of liver fibrosis progression were determined. These parameters were 
related to chosen genpolymorphism of IL-10 (G/A -1082; C/T -819; -592 C/A), rate of 
fibrosis progression and prevalence of fibrosis  
Results 
The IL-10 G / A -1082 genotypes AA, GA and GG showed no difference in prevalence of 
liver fibrosis (74.4 to 85.2%), the rate of fibrosis progression and the relative risk fibrosis 
(1.04 to 1.1 old  increases) detectable. At IL-10 C/T -819 the three genotype TT, CT and 
CC showed no difference in the rate of fibrosis. However, the fibrosis progression in TT 
was 1.5 fibrosis-classes per year higher than CT (0.9) or CC (1.1). The relative risk for liver 
fibrosis did not differ (1.09 to 1,15fold).  
The IL-10 C/A -592 Genotype CA led the least likely to liver fibrosis (68.5%), while patients 
with CC (82.5%) and AA genotype (88.2%) more often developed a liver fibrosis.  
The AA genotype led to a higher fibrosis progression rate (1.6 fibrosis classes / year) than 
the CA (0.9 classes) or CC genotype (1.1 classes). However, the relative risk of fibrosis 
was 0, 93 times lower than the CC genotype compared to AA. 
Conclusions 
The IL-10 G / A -1082 genotypes AA, GA and GG showed no difference in prevalence of 
liver fibrosis, the rate of fibrosis progression and the relative risk fibrosis detectable. At IL-
10 C/T -819 the three genotype TT, CT and CC showed no difference in the rate of 
fibrosis. However, the fibrosis progression in TT was 1.5 fibrosis-classes per year higher 
than CT or CC. The relative risk for liver fibrosis did not differ. 
The IL-10 C/A -592 Genotype CA led least likely to liver fibrosis, while patients with CC 
and AA genotype more often developed a liver fibrosis. The AA genotype led to a higher 
fibrosis progression rate . The relative risk of fibrosis was lower than the CC genotype 
compared to AA. 
 
